INDV — Indivior Pharmaceuticals Inc

Summary of Indivior Pharmaceuticals Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Financials: Total net revenue was $358 million, a 20% increase year-over-year. For the full year, total net revenue reached approximately $1.24 billion, up 4% from 2024.
• SUBLOCADE Performance: Q4 net revenue for SUBLOCADE was $252 million, reflecting a 30% increase year-over-year, while full-year revenue was $856 million, a 13% increase.
• Adjusted EBITDA: Grew 91% year-over-year in Q4 to $142 million, with a full-year increase of 20% to $428 million, achieving a margin improvement of 500 basis points.
• Operating Expenses: Non-GAAP operating expenses were $164 million for Q4 and $622 million for the full year, down 8% and 5% respectively, due to organizational simplifications.

2. Strategic Updates and Business Highlights

• Indivior Action Agenda: The company has completed Phase 1 ("Generate Momentum") and is now executing Phase 2 ("Accelerate") of its strategic plan, focusing on enhancing SUBLOCADE's market presence.
• Direct-to-Consumer Campaign: Launched the "Move Forward in Recovery" campaign in October 2025, aimed at increasing awareness and engagement for SUBLOCADE, showing early positive indicators.
• Market Position: SUBLOCADE is the leading long-acting injectable for opioid use disorder, with over 475,000 prescriptions. The company aims to leverage its 12 patents expiring between 2031 and 2038 to sustain growth.

3. Forward Guidance and Outlook

• 2026 Expectations: Indivior anticipates total net revenue between $1.125 billion and $1.195 billion, with SUBLOCADE net revenue projected to grow by 8% to a range of $905 million to $945 million.
• Dispense Unit Growth: Expected mid-teens growth in SUBLOCADE dispense units, up from 7% in 2025, with adjusted EBITDA projected to grow by 30% in 2026.
• Capital Deployment: A new $400 million share repurchase program has been authorized, alongside plans to manage debt and explore business development opportunities.

4. Bad News, Challenges, or Points of Concern

• Market Pressures: Anticipated pressure on SUBOXONE Film revenue due to generic competition, which may impact overall revenue growth.
• Gross-to-Net Dynamics: In 2026, gross-to-net is expected to serve as a headwind, contrasting with its tailwind effect in 2025.
• Regulatory and Funding Landscape: Concerns regarding potential Medicaid funding cuts in 2027 could impact future growth, although the company remains optimistic about the overall supportive legislative environment for opioid use disorder treatments.

5. Notable Q&A Insights

• Market Penetration: CEO Joseph Ciaffoni indicated that long-acting injectables (LAIs) are currently underutilized, with potential penetration rates projected between 20%-30% based on comparisons to other therapeutic areas.
• Competitive Landscape: Indivior's market share for SUBLOCADE has stabilized in the mid-70s, with a focus on new patient starts showing strong growth.
• Business Development Focus: The company is looking for commercial-stage assets in new therapeutic areas, emphasizing the need for differentiated products with significant peak sales potential and a long runway for growth.

This summary encapsulates the key points from Indivior's Q4 2025 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.